
MeiraGTx Holdings PLC (NASDAQ:MGTX – Free Report) – Stock analysts at HC Wainwright reduced their FY2026 EPS estimates for MeiraGTx in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.10 for the year, down from their previous forecast of $0.36. The consensus estimate for MeiraGTx’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.18) EPS and FY2027 earnings at ($1.83) EPS.
Other analysts have also recently issued research reports about the stock. Zacks Research cut shares of MeiraGTx from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 11th. Wall Street Zen lowered MeiraGTx from a “buy” rating to a “hold” rating in a research report on Saturday. Royal Bank Of Canada raised their price objective on MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday, August 14th. The Goldman Sachs Group assumed coverage on MeiraGTx in a research note on Thursday, September 24th. They set a “neutral” rating and a $16.00 price target for the company. Finally, Weiss Ratings cut MeiraGTx from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.00.
MeiraGTx Stock Performance
MGTX opened at $8.74 on Tuesday. The stock has a market capitalization of $839.39 million, a price-to-earnings ratio of 10.92 and a beta of 1.09. The company has a fifty day moving average of $10.61 and a 200 day moving average of $10.37. MeiraGTx has a fifty-two week low of $6.62 and a fifty-two week high of $15.35. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.76 and a current ratio of 3.76.
MeiraGTx (NASDAQ:MGTX – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.03). MeiraGTx had a return on equity of 154.51% and a net margin of 19.46%. The company had revenue of $4.81 million during the quarter, compared to analysts’ expectations of $6.95 million.
Insider Buying and Selling at MeiraGTx
In related news, CFO Richard Giroux sold 56,000 shares of the business’s stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $9.95, for a total value of $557,200.00. Following the sale, the chief financial officer owned 852,530 shares in the company, valued at approximately $8,482,673.50. The trade was a 6.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $10.64, for a total transaction of $294,291.76. Following the sale, the insider directly owned 613,187 shares in the company, valued at approximately $6,524,309.68. The trade was a 4.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.40% of the company’s stock.
Institutional Trading of MeiraGTx
Large investors have recently made changes to their positions in the business. Squarepoint Ops LLC boosted its holdings in shares of MeiraGTx by 773.9% in the 2nd quarter. Squarepoint Ops LLC now owns 162,412 shares of the company’s stock worth $2,194,000 after purchasing an additional 143,828 shares during the period. Johnson & Johnson purchased a new stake in MeiraGTx during the 2nd quarter valued at $89,720,775. Tocqueville Asset Management L.P. purchased a new stake in MeiraGTx during the 2nd quarter valued at $1,050,000. Bank of America Corp DE bought a new stake in MeiraGTx in the second quarter worth $3,914,000. Finally, Sei Investments Co. bought a new stake in MeiraGTx in the first quarter worth $863,000. 67.48% of the stock is currently owned by institutional investors.
MeiraGTx Company Profile
MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.
See Also
- Five stocks we like better than MeiraGTx
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
